Asia Green Biotechnology Corp., an early stage international agri-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology in Asia. It focuses on planting, growing, and harvesting new and valuable strains of hemp and related crops. Asia Green Biotechnology Corp. has an agreement with Pathway Rx Inc. and PNW Biosciences Inc. for the clinical development and commercialization of the cannabis sativa varieties for prevention and treatment of COVID-19 and other infectious diseases. The company was formerly known as Asia Cannabis Corp. and changed its name to Asia Green Biotechnology Corp. in April 2020. The company was incorporated in 2017 and is based in Calgary, Canada.